Bexarotene
- PDF / 141,373 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 112 Downloads / 159 Views
1
S
Fatal Hodgkin’s lymphoma?: case report A 44-year-old man developed Hodgkin’s lymphoma, and subsequently died, following treatment with bexarotene for Sezary syndrome. The man was diagnosed with Sezary syndrome in 2006, and received chemotherapy until 2008. From 2008, his disease was stable for 12 months under treatment with vorinostat, photochemotherapy and interferon-α-2a. Four months after discontinuing vorinostat, he commenced bexarotene 525 mg/day [route not stated], with interferonα-2a and photochemotherapy. After 3 months of treatment, his peripheral blood smear revealed no Sezary cells and his skin involvement severity had decreased. Four months after bexarotene initiation, his inguinal lymph nodes were severely enlarged. Ultrasonography revealed an increase in the size and number of inguinal and axillary nodes from examinations done 3 months earlier. CT scan showed enlarged inguinal, para-aortic, axillary and parailiac lymph nodes. Histopathology showed mixed cellular Hodgkin’s lymphoma. The man received bleomycin, doxorubicin, dacarbazine and vinblastine, but he died 1 week after chemotherapy. Author comment: "In the present case, the temporal relation implicates bexarotene may be the cause." Sanli H, et al. Development of Hodgkin’s lymphoma under bexarotene treatment for Sezary syndrome and review of the literature. Journal of Drugs in Dermatology 803038879 9: 1014-6, No. 8, Aug 2010 - Turkey
0114-9954/10/1320-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 25 Sep 2010 No. 1320
Data Loading...
